Pharmacological treatment of the ion transport defect in cystic fibrosis

Expert Opinion on Investigational Drugs

Volumn 10, Issue 1, 2001, Pages 1-19

  Roomans, G M ^a  

^a UPPSALA UNIVERSITY   (Sweden)

Author keywords

4 Phenylbutyrate; Airway epithelium; Amiloride; Bicarbonate; Chaperones; Chloride transport; Cystic fibrosis; Cystic fibrosis transmembrane conductance regulator; Genistein; Purinergic agonists; Sodium transport; Xanthines

Indexed keywords

1,3 DIALLYL 8 CYCLOHEXYLXANTHINE; 4 PHENYLBUTYRIC ACID; 8 CYCLOPENTYL 1,3 DIPROPYLXANTHINE; ADENOSINE A1 RECEPTOR ANTAGONIST; ADENOSINE TRIPHOSPHATE; AMILORIDE; AMILORIDE DERIVATIVE; ANTIBODY CONJUGATE; B 43 GENISTEIN; BICARBONATE; BUPHENYL; CALYCULIN A; CD19 ANTIGEN; CHAPERONE; CHLORIDE CHANNEL; FLAVONOL; GENISTEIN; ISOBUTYLMETHYLXANTHINE; ISOFLAVONE; ISOPRENALINE; LEVAMISOLE; ORTHOVANADIC ACID; PROTEASOME; PROTEIN TYROSINE KINASE INHIBITOR; PURINE; SODIUM ION; TRANSMEMBRANE CONDUCTANCE REGULATOR; UBIQUITIN; UNCLASSIFIED DRUG; UNINDEXED DRUG; URIDINE TRIPHOSPHATE; WATER; XANTHINE;

ANIMAL CELL; APICAL MEMBRANE; CYSTIC FIBROSIS; DEATH; DRUG HALF LIFE; DRUG INHIBITION; DRUG MECHANISM; DRUG RECEPTOR BINDING; DRUG RESEARCH; DRUG STRUCTURE; ENDOPLASMIC RETICULUM; EPITHELIUM; EPITHELIUM CELL; GENE MUTATION; HUMAN; HUMAN CELL; ION TRANSPORT; NONHUMAN; PROTEIN FOLDING; PROTEIN SECRETION; RESPIRATORY EPITHELIUM; REVIEW; SODIUM ABSORPTION; WATER TRANSPORT;

AMILORIDE; BICARBONATES; CYSTIC FIBROSIS; CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR; GENISTEIN; HUMANS; ION TRANSPORT; PHENYLBUTYRATES; XANTHINES;

EID: 0035191641     PISSN: 13543784     EISSN: None     Source Type: Journal    
DOI: 10.1517/13543784.10.1.1     Document Type: Review

References (159)

1. Cystic fibrosis: A disease in electrolyte transport
2. Identification of the cystic fibrosis gene: Cloning and characterization of complementary DNA
3. Cystic fibrosis: Current survival and population estimates to the year 2000
4. Physiology of cystic fibrosis
5. Cystic fibrosis: Molecular biology and therapeutic implications
6. The two nucleotide-binding domains of cystic fibrosis transmembrane conductance regulator (CFTR) have distinct functions in controlling channel activity
7. Structure and function of the CFTR chloride channel
8. Biosynthesis and degradation of CFTR
9. Cystic fibrosis as a disease of misprocessing of the cystic fibrosis transmembrane conductance regulator glycoprotein
10. Defects in processing and trafficking of the cystic fibrosis transmembrane conductance regulator
11. The common variant of cystic fibrosis transmembrane conductance regulator is recognized by hsp70 and degraded in a pre-Golgi lysosomal compartment
12. Participation of the endoplasmic reticulum chaperone calnexin (p88, IP90) in the biogenesis of the cystic fibrosis transmembrane conductance regulator
13. Perturbation of Hsp90 interaction with nascent CFTR prevents its maturation and accelerates its degradation by the proteasome
14. The Hdj-2/Hsc70 chaperone pair facilitates early steps in CFTR biogenesis
15. Defective intracellular transport and processing of CFTR is the molecular basis of most cystic fibrosis
16. Multiple proteolytic systems, including the proteasome, contribute to CFTR processing
17. Degradation of CFTR by the ubiquitin-proteasome pathway
18. Processing of mutant cystic fibrosis transmembrane conductance regulator is temperature-sensitive
19. Chemical chaperones correct the mutant phenotype of the ΔF508 cystic fibrosis transmembrane conductance regulator protein
20. Molecular mechanisms of CFTR chloride channel dysfunction in cystic fibrosis
21. Role of CFTR in airway disease
22. A pilot study of aerosolized amiloride for the treatment of lung disease in cystic fibrosis
23. - channel function
24. Evidence for periciliary liquid layer depletion, not abnormal ion composition, in the pathogenesis of cystic fibrosis airways disease
25. Osmotic water permeabilities of cultured, well-differentiated normal and cystic fibrosis airway epithelia
26. Cystic fibrosis epithelia fail to kill bacteria because of abnormal airway surface fluid
27. Loss of CFTR chloride channels alters salt absorption by cystic fibrosis airway epithelia in vitro
28. Influence of molecular and chemical chaperones on protein folding
29. Glycerol reverses the misfolding phenotype of the most common cystic fibrosis mutation
30. Surface expression of the cystic fibrosis transmembrane conductance regulator mutant ΔF508 is markedly upregulated by combination treatment with sodium butyrate and low temperature
31. Functional activation of the cystic fibrosis trafficking mutant ΔF508-CFTR by overexpression
32. In vitro pharmacologic restoration of CFTR-mediated chloride transport with sodium 4-phenylbutyrate in cystic fibrosis epithelial cells containing ΔF508-CFTR
33. A pilot clinical trial of oral sodium 4-phenylbutyrate (Buphenyl) in ΔF508-homozygous cystic fibrosis patients: Partial restoration of nasal epithelial CFTR function
34. Defective function of the cystic fibrosis-causing missense mutation G551D is recovered by genistein
35. Activation of ΔF508 CFTR in a cystic fibrosis respiratory epithelial cell line by 4-phenylbutyrate, genistein and CPX
36. Sodium 4-phenylbutyrate downregulates Hsc70: Implications for intracellular trafficking of ΔF508-CFTR
37. - secretion in Calu-3 airway epithelial cells
38. Butyrate increases apical membrane CFTR but reduces chloride secretion in MDCK cells
39. G(1) Phase growth arrest and induction of p21(Waf1/Cip1/Sdi1) in IB3-1 cells treated with 4-sodium phenylbutyrate
40. Cytotoxic effects of sodium phenylbutyrate on human neuroblastoma cell lines
41. Inhibitory effects of phenylbutyrate on the proliferation, morphology, migration and invasiveness of malignant glioma cells
42. Pharmacologic restoration of ΔF508 CFTR-mediated chloride current
43. Focus on 'Sodium 4-phenylbutyrate downregulates Hsc70: Implications for intracellular trafficking of ΔF508-CFTR'
44. Defective beta-adrenergic secretory responses in submandibular acinar cells from cystic fibrosis patients
45. Decreased beta-adrenergic stimulation of glycoprotein secretion in CF mice submandibular glands: Reversal by the methylxanthine, IBMX
46. Molecular basis of defective anion transport in L cells expressing recombinant forms of CFTR
47. Isobutylmethylxanthine fails to stimulate chloride secretion in cystic fibrosis airway epithelia
48. ΔF508-CFTR channels: Kinetics, activation by forskolin and potentiation by xanthines
49. Cystic fibrosis transmembrane conductance regulator activation by cAMP-independent mechanisms
50. Structural basis for specificity and potency of xanthine derivatives as activators of the CFTR chloride channel
51. Pharmacology of CFTR chloride channel activity
52. A1 adenosine-receptor antagonists activate chloride efflux from cystic fibrosis cells
53. A1 receptor antagonist 8-cyclopentyl-1,3-dipropyl xanthine selectively activates chloride efflux from human epithelial and mouse fibroblast cell lines expressing the cystic fibrosis transmembrane regulator ΔF508 mutation
54. Stimulation by alkylxanthines of chloride efflux in CFPAC-1 cells does not involve A1 adenosine receptors
55. Actions of adenosine A1 and A2 receptor antagonists on CFTR antibody-inhibited beta-adrenergic mucin secretion response
56. CPX, a selective A1-adenosine-receptor antagonist, regulates intracellular pH in cystic fibrosis cells
57. 8-Cyclopentyl-1,3-dipropylxanthine and other xanthines differentially bind to the wild-type and ΔF508 first nucleotide binding fold (NBF-1) domains of the cystic fibrosis transmembrane conductance regulator
58. Direct activation of cystic fibrosis transmembrane conductance regulator channels by 8-cyclopentyl-1,3-dipropylxanthine (CPX) and 1,3-diallyl-8-cyclohexylxanthine (DAX)
59. Pharmacogenomics of the cystic fibrosis transmembrane conductance regulator (CFTR) and the cystic fibrosis drug CPX using genome microarray analysis
60. No evidence for direct activation of the cystic fibrosis transmembrane conductance regulator by 8-cyclopentyl-1,3-dipropyl xanthine
61. Genistein, a specific inhibitor of tyrosine-specific protein kinases
62. Inhibition of tyrosine protein kinase activity by synthetic isoflavones and flavones
63. Use and specificity of genistein as inhibitor of protein-tyrosine kinases
64. Inhibitory effects of the tyrosine kinase inhibitor genistein on mammalian DNA topoisomerase II
65. Defining functional drug-interaction domains on topoisomerase II by exploiting mechanistic differences between drug classes
66. Effects of isoflavone compounds on the activation of phospholipase C
67. Genistein, an inhibitor of protein tyrosine kinase, is also a competitive antagonist for P1-purinergic (adenosine) receptor in FRTL-5 thyroid cells
68. Interactions of flavonoids and other phytochemicals with adenosine receptors
69. Soy intake and cancer risk: A review of the in vitro and in vivo data
70. Legumes and soybeans: Overview of their nutritional profiles and health effects
71. Stimulation of secretion by the T84 colonic epithelial cell line with dietary flavonols
72. Citrus flavonoids stimulate secretion by human colonic T84 cells
73. cAMP-independent activation of CFTR C1 channels by the tyrosine kinase inhibitor genistein
74. Tyrosine phosphorylation is a novel pathway for regulation of chloride secretion in shark rectal gland
75. - secretion in T84 cell monolayers
76. - secretion in rat distal colon by genistein, a protein tyrosine kinase inhibitor
77. Direct action of genistein on CFTR
78. Actions of genistein on cystic fibrosis transmembrane conductance regulator channel gating. Evidence for two binding sites with opposite effects
79. Genistein directly induces cardiac CFTR chloride current by a tyrosine kinase-independent and protein kinase A-independent pathway in guinea pig ventricular myocytes
80. - channels via a tyrosine kinase- and protein phosphatase-independent mechanism
81. Expression and regulation of chloride channels in neonatal rat cardiomyocytes
82. - conductance through CFTR in human airway epithelia
83. Inhibition of ATPase, GTPase and adenylate kinase activities of the second nucleotide-binding fold of the cystic fibrosis transmembrane conductance regulator by genistein
84. Genistein potentiates wild-type and ΔF508-CFTR channel activity
85. Vasoactive intestinal peptide, forskolin and genistein increase apical CFTR trafficking in the rectal gland of the spiny dogfish, Squalus acanthias. Acute regulation of CFTR trafficking in an intact epithelium
86. Modulation of CFTR chloride channels by calyculin A and genistein
87. Flavonoids stimulate C1 conductance of human airway epithelium in vitro and in vivo
88. - secretion in the murine trachea and colon
89. Pharmacological modulation of ion transport across wild-type and ΔF508 CFTR-expressing human bronchial epithelia
90. Activation of cystic fibrosis transmembrane conductance regulator in rat epididymal epithelium by genistein
91. - channels expressed in murine cell line
92. Alternate stimulation of apical CFTR by genistein in epithelia
93. Clinical development plan: Genistein
94. In vivo toxicity and pharmacokinetic features of B43 (anti-CD19)-genistein immunoconjugate in non-human primates
95. Treatment of therapy-refractory B-lineage acute lymphoblastic leukemia with an apoptosis-inducing CD19-directed tyrosine kinase inhibitor
96. - channel by specific protein kinases and protein phosphatases
97. CFTR chloride channel activation by genistein: The role of serine/threonine protein phosphatases
98. Possible regulation of CFTR-chloride channels by membrane-bound phosphatases in pancreatic duct cells
99. Phosphatase inhibitors activate normal and defective CFTR chloride channels
100. 2+-independent activation of cystic fibrosis transmembrane conductance regulator channels by phenylimidazothiazole drugs
101. Regulation of CFTR by protein phosphatase 2B and protein kinase C
102. Activation of endogenous ΔF508 cystic fibrosis transmembrane conductance regulator by phosphodiesterase inhibition
103. The in vivo effects of milrinone on the airways of cystic fibrosis mice and human subjects
104. 2+-dependent K+ channels by novel benzimidazolone
105. The substituted benzimidazolone NS004 is an opener of the cystic fibrosis chloride channel
106. - Channel activity compensates for defective processing in a cystic fibrosis mutant corresponding to a mild form of the disease
107. - Secretion by benzimidazolones. II. Coordinate regulation of apical GC1 and basolateral GK
108. - Secretion by chlorzoxazone
109. Psoriasis: Current perspectives with an emphasis on treatment
110. Psoralen pharmacology: Studies on metabolism and enzyme induction
111. 8-Methoxypsoralen blocks ATP-sensitive potassium channels and stimulates insulin release
112. - Secretion
113. Development of substituted Benzo[c]quinolizinium compounds as novel activators of the cystic fibrosis chloride channel
114. Suppression of a CFTR premature stop mutation in a bronchial epithelial cell line
115. A pilot study of the effect of gentamicin on nasal potential difference measurements in cystic fibrosis patients carrying stop mutations
116. - Channel in mouse 3T3 fibroblasts
117. Familial Mediterranean fever at the millennium. Clinical spectrum, ancient mutations and a survey of 100 American referrals to the national institutes of health
118. Induction by antitumoral drugs of proteins that functionally complement CFTR: A novel therapy for cystic fibrosis?
119. Interest of colchicine for the treatment of cystic fibrosis patients. Preliminary report
120. Inflammation and CFTR: Might neutrophils be the key in cystic fibrosis?
121. Altered regulation of airway epithelial chloride channels in cystic fibrosis
122. Chloride secretory response of cystic fibrosis human airway epithelia. Preservation of calcium but not protein kinase C- and A-dependent mechanisms
123. Regulation of transepithelial ion transport and intracellular calcium by extracellular ATP in human normal and cystic fibrosis airway epithelium
124. Characterization of immortal cystic fibrosis tracheobronchial gland epithelial cells
125. Extracellular UTP stimulates electrogenic bicarbonate secretion across CFTR knockout gallbladder epithelium
126. Activation by extracellular nucleotides of chloride secretion in the airway epithelia of patients with cystic fibrosis
127. Effect of uridine-5'-triphophate plus amiloride on mucociliary clearance in adult cystic fibrosis
128. Acute safety and effects on mucociliary clearance of aerosolized uridine-5'-triphophate ± amiloride in normal human adults
129. Sodium channel blockers and uridine triphosphate: Effects on nasal potential difference in cystic fibrosis mice
130. Epithelial P2X purinergic receptor channel expression and function
131. Regulation of intracellular calcium by extracellular nucleotides in cultured pig tracheal submucosal gland cells
132. + absorption in distal bronchi
133. + absorption in wild-type and ΔF508 CFTR-expressing human bronchial epithelia
134. Adenosine triphosphate: Established and potential clinical applications
135. Acute and long-term amiloride inhalation in cystic fibrosis lung disease. A rational approach to cystic fibrosis therapy
136. Amiloride inhalation therapy in cystic fibrosis. Influence on ion content, hydration and rheology of sputum
137. Effect of amiloride and saline on nasal mucociliary clearance and potential difference in cystic fibrosis and normal subjects
138. Aerosolized amiloride: Dose effect on nasal bioelectric properties, pharmacokinetics and effect on sputum expectoration in patients with cystic fibrosis
139. Effects of topically delivered benzamil and amiloride on nasal potential difference in cystic fibrosis
140. Pharmacologic modulation of salt and water in the airway epithelium in cystic fibrosis
141. Physical and functional properties of airway secretions in cystic fibrosis - Therapeutic approaches
142. No added benefit from nebulized amiloride in patients with cystic fibrosis
143. Nebulised amiloride in respiratory exacerbations of cystic fibrosis: A randomised controlled trial
144. French multicenter randomized double-blind placebo-controlled trial on nebulized amiloride in cystic fibrosis patients. The Amiloride-AFLM collaborative s0tudy group
145. Benzamil and mucoviscidosis. Primary culture of nasal mucosa as an electrophysiologic in vitro model
146. The effect of topical benzamil and amiloride on nasal potential difference in cystic fibrosis
147. + transport across airway epithelia
148. Inhibition of airway liquid secretion and its effect on the physical properties of airway mucus
149. CFTR involvement in chloride, bicarbonate and liquid secretion by airway submucosal glands
150. Bicarbonate and chloride secretion in Calu-3 human airway epithelial cells
151. Anion selectivity of apical membrane conductance of Calu 3 human airway epithelium
152. - Exchange activity in tracheal epithelial cells
153. Identification of transport abnormalities in duodenal mucosa and duodenal enterocytes from patients with cystic fibrosis
154. Partial restoration of cAMP-stimulated CFTR chloride channel activity in ΔF508 cells by deoxyspergualin
155. Post-translational disruption of the ΔF508 cystic fibrosis transmembrane conductance regulator (CFTR)-molecular chaperone complex with geldanamycin stabilizes ΔF508 CFTR in the rabbit reticulocyte lysate
156. Retrograde protein translocation: Eradication of secretory proteins in health and disease
157. Quantitative fluorescence measurements of chloride secretion in native airway epithelium from CF and non-CF subjects
158. Measurements of CFTR activity in nasal epithelial cells by MQAE
159. Assessment of CFTR function in nasal epithelium